H.B. Fuller’s Valuations And Margins Driven By EV Momentum Earns It Analyst Conviction
Citigroup analyst Eric Petrie upgraded H.B. Fuller Co (NYSE:FUL) from Neutral to Buy and raised the price target from $72 to $85.…
Citigroup Upgrades Stanley Black & Decker to Neutral, Raises Price Target to $106
Citigroup analyst Eric Lau upgrades Stanley Black & Decker (NYSE:SWK) from Sell to Neutral and raises the price target from $69 to $106.
CBRE Upgrades Boyd Gaming to Buy, Announces $75 Price Target
CBRE analyst John DeCree upgrades Boyd Gaming (NYSE:BYD) from Hold to Buy and announces $75 price target.
UBS Upgrades International Paper to Neutral, Raises Price Target to $43
UBS analyst Cleve Rueckert upgrades International Paper (NYSE:IP) from Sell to Neutral and raises the price target from $31 to $43.
Morgan Stanley Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $130
Morgan Stanley analyst Jeffrey Hung upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Equal-Weight to Overweight and raises the price target from $120 to $130.
Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target
Morgan Stanley analyst Jeffrey Hung upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Equal-Weight and announces $9 price target.
Citigroup Upgrades H.B. Fuller to Buy, Raises Price Target to $85
Citigroup analyst Eric Petrie upgrades H.B. Fuller (NYSE:FUL) from Neutral to Buy and raises the price target from $72 to $85.
Baird Upgrades Cardinal Health to Outperform, Raises Price Target to $94
Baird analyst Eric Coldwell upgrades Cardinal Health (NYSE:CAH) from Neutral to Outperform and raises the price target from $87 to $94.
‘The Year Of The Efficient Rabbit’: Why Analysts Are Raising Their Price Targets On Meta Platforms (Including One Doubling The PT)
Social media and metaverse company Meta Platforms Inc (NASDAQ: META) reported fourth quarter financial results and first quarter guidance af
Goldman Sachs Upgrades Align Tech to Neutral, Announces $307 Price Target
Goldman Sachs analyst Nathan Rice upgrades Align Tech (NASDAQ:ALGN) from Sell to Neutral and announces $307 price target.